SCHEMBL1964183

SCHEMBL1964183

CC(C)(C)OC(=O)N1C(C)(C)CC(N)CC1(C)C

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 2/20 0.38
CHRM2 P08172 1/20 0.38
CHRM1 P11229 1/20 0.38
CHRM3 P20309 1/20 0.38
EPHX2 P34913 1/20 0.37
USP2 O75604 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CTSK P43235 1/20 0.36
NR1H2 P55055 2/20 0.35
HPGD P15428 1/20 0.34
BUB1 O43683 1/20 0.33
KDM4E B2RXH2 1/20 0.33
MAPT P10636 1/20 0.33
THRB P10828 1/20 0.33
RECQL P46063 1/20 0.33
EPHX1 P07099 1/20 0.33
PREP P48147 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15769252 0.84 CHRM2 (0.46) KDM1ACHRM2CHRM1CHRM3EPHX2
SCHEMBL22214267 0.83 KDM1A (0.39) KDM1ACHRM2CHRM1CHRM3EPHX2
SCHEMBL28484797 0.83 KDM1A (0.39) KDM1ACHRM2CHRM1CHRM3EPHX2
SCHEMBL25176823 0.83 KDM1A (0.39) KDM1ACHRM2CHRM1CHRM3EPHX2
SCHEMBL21162862 0.82 CHRM2 (0.38) KDM1ACHRM2CHRM1CHRM3EPHX2
SCHEMBL4484103 0.77 KDM1A (0.38) KDM1ACHRM2CHRM1CHRM3EPHX2
SCHEMBL10991831 0.76 GAA (0.39) CHRM1SMN1; SMN2KDM4ETHRB
SCHEMBL16468545 0.76 CTSK (0.42) CHRM2CHRM1CHRM3EPHX2USP2
SCHEMBL21163251 0.74 CHRM2 (0.39) CHRM2CHRM1CHRM3EPHX2USP2
SCHEMBL16414603 0.74 NR1H2 (0.40) CHRM2CHRM1CHRM3EPHX2USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8987251-B2 Triazolopyridine compounds as PIM kinase inhibitors ARRAY BIOPHARMA INC. (US) 2015-03-24 US disclosed
US-20140045817-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2014-02-13 US disclosed
US-8575145-B2 Triazolopyridine compounds as PIM kinase inhibitors ARRAY BIOPHARMA INC. (US) 2013-11-05 US disclosed
EP-2334677-B1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2013-10-09 EP disclosed
CN-102186851-B Triazolopyridine compounds as pim kinase inhibitors ARRAY BIOPHARMA INC 2013-06-12 CN disclosed
CN-102186851-A Triazolopyridine compounds as pim kinase inhibitors ARRAY BIOPHARMA INC 2011-09-14 CN disclosed
EP-2334677-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS Array Biopharma, Inc. (US) 2011-06-22 EP disclosed
US-20110144085-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2011-06-16 US disclosed
WO-2010022076-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2010-02-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144085-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS PIM1, PIM2, PIM3 KDM1A 655/4885CHRM2 573/4885CHRM1 445/4885
US-20140045817-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS PIM2, PIM1, PIM3 KDM1A 659/4885CHRM2 1458/4885CHRM1 1250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.